$64.89
-$0.35
(-0.54%)
Quote as of 4:04 PM EST on 02/09/12
Johnson & Johnson
NYSE:JNJ
Extended Hours:
$64.51
-$0.38
(-0.59%)
Quote as of 5:24 AM EST on 02/10/12 (NYSE)
Invest Like Buffett: No Looking Back
Leerink's biotech and pharmaceuticals analysts hold a conference call
Be careful what you wish for Ron Paul. What a world on the gold standard may look like
Johnson & Johnson to Participate in 2012 Leerink Swann Global Health Care Conference
5 Undervalued Dividend Stocks For Income And A 20% Gain
Johnson & Johnson to Participate in 2012 Leerink Swann Global Health Care Conference
Analysts' 5 Favorite Stocks With Strong Dividend Growth
Cramer's Mad Money - What Keeps Me Up At Night (2/8/12)
Top Dividend Stocks From The Neuberger Berman Equity Income Fund
Watson reaches settlement with Janssen over generic Ortho Tri-Cyclen LO
12 Dividend Companies With Large Patent Shields
Buy Dividend Stocks as Market 'Smells Like Speculation'
10 Pharma Stocks to Add to Your Portfolio…Stat
Elan Reports Fourth Quarter and Full-Year 2011 Financial Results
5 Dogs Of Dow That Are Dividend Traps
Top-Rated Stocks Going Ex-Dividend In February
Blue Chips Headed for Dividend Hikes?
Argus Research's healthcare analyst holds a conference call
Dividend Inspiration From The Prudential Jennison Equity Income Fund
Investing In The Dogs Of The Dow
Smith & Nephew in $22m bribes fine
Stability In A Volatile Year: 5 Stocks Trading At A Relative Discount
Earnings Scorecard: Johnson & Johnson - Analyst Blog
Johnson & Johnson sued in China over alleged price fixing, Shanghai Daily says
Overreacting to a Prostate Cancer Drug?
Johnson & Johnson Hid Risperdal Studies to Boost Drug Sales, Lawyer Says
J&J Hid Risperdal Studies to Boost Drug Sales, Lawyer Says at N.J. Trial
da Vinci reimbursement set for April in Japan, says Collins Stewart
FDA and industry reach agreement in principle on medical device user fees
Merck's Risky Cost Cutting Move
Johnson & Johnson downgraded to Market Perform from Outperform at First Global
U.K. agency says it can't justify pricey J&J cancer drug, Bloomberg reports
What Abbott Needs Now: A New CEO
